Ganglioside GD2 Antibodies

Santa Cruz Biotechnology provides a broad selection of Ganglioside GD2 monoclonal antibodies for research applications. Ganglioside GD2 monoclonal antibodies are compatible with multiple experimental techniques, including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). Ganglioside GD2 is a glycosphingolipid that functions in cell signaling and is primarily expressed in the nervous system and specific tumors. The presence of Ganglioside GD2 has emerged as a significant focus in cancer research, particularly in neuroblastoma and melanoma studies. Research has shown that Ganglioside GD2 expression correlates with tumor progression and metastasis, establishing its significance as a biomarker for diagnosis. The molecule's unique characteristics make it a promising target for immunotherapy development. Ongoing research continues to uncover new insights about Ganglioside GD2's role in cellular processes and disease mechanisms. Current investigations are expanding knowledge about its involvement in various cancer types and potential therapeutic applications. Santa Cruz Biotechnology monoclonal antibodies enable researchers worldwide to advance scientific understanding of Ganglioside GD2's role in cancer biology and therapeutic development.